These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 816581)

  • 1. Alternative complement pathway activity in sera from patients with sickle cell disease.
    Koethe SM; Casper JT; Rodey GE
    Clin Exp Immunol; 1976 Jan; 23(1):56-60. PubMed ID: 816581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Complement and serum immunoglobulins in homozygous and heterozygous sickle cell anemia in Senegal].
    Dieye TN; Ndiaye O; Ndiaye AB; Thiam D; Fall-Seck K; Diop S; Diop BM; Fall M; Diakhaté L
    Dakar Med; 1999; 44(2):175-9. PubMed ID: 11957280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative pathway of complement in sickle cell disease.
    Strauss RG; Asbrock T; Forristal J; West CD
    Pediatr Res; 1977 Apr; 11(4):285-9. PubMed ID: 846782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The alternative pathway of complement activation in the neonate.
    Feinstein PA; Kaplan SR
    Pediatr Res; 1975 Oct; 9(10):803-6. PubMed ID: 1103071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of the alternate pathway in chelated serum.
    Forsgren A; Mclean RH; Michael AF; Quie PG
    J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
    Whaley K; Schur PH; Ruddy S
    J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma haemoglobin and complement activation in sickle cell disease.
    DeCeulaer K; Wilson WA; Morgan AG; Serjeant GR
    J Clin Lab Immunol; 1981 Jul; 6(1):57-60. PubMed ID: 7265176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formation and function of a complex of the C3 proactivator with a protein from cobra venom.
    Cooper NR
    J Exp Med; 1973 Feb; 137(2):451-60. PubMed ID: 4734404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the alternative pathway of complement in childhood acute lymphoblastic leukemia.
    Kalwinsky DK; Urmson JR; Stitzel AE; Spitzer RE
    J Lab Clin Med; 1976 Nov; 88(5):745-56. PubMed ID: 1068203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the alternative complement pathway in systemic lupus erythematosus.
    Wilson MR; Arroyave CM; Nakamura RM; Vaughan JH; Tan EM
    Clin Exp Immunol; 1976 Oct; 26(1):11-20. PubMed ID: 826360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B.
    Daha MR; Fearon DT; Austen KF
    Immunology; 1976 Nov; 31(5):789-96. PubMed ID: 992711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficiency of serum bactericidal activity against Salmonella typhimurium in sickle cell anaemia.
    Hand WL; King NL
    Clin Exp Immunol; 1977 Nov; 30(2):262-70. PubMed ID: 342154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunological study in sickle cell disease patients: importance of the complement system].
    Sassi F; Bardi R; Neji T; Ayed K; Ben Dridi MF
    Tunis Med; 2003 Mar; 81(3):195-9. PubMed ID: 12793071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breakdown products of C3 and factor B in hemolytic-uremic syndrome.
    Kim Y; Miller K; Michael AF
    J Lab Clin Med; 1977 Apr; 89(4):845-50. PubMed ID: 845484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyanate as an inactivator of complement proteins.
    Schultz DR; Arnold PI
    J Immunol; 1975 Dec; 115(6):1558-65. PubMed ID: 1184967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.
    Ruddy S; Austen KF; Goetzl EJ
    J Clin Invest; 1975 Mar; 55(3):587-92. PubMed ID: 1167871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C3 requirements for formation of alternative pathway C5 convertase.
    Daha MR; Fearon DT; Austen KF
    J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of chrysotile asbestos fibres with the complement system.
    Saint-Remy JM; Cole P
    Immunology; 1980 Oct; 41(2):431-7. PubMed ID: 6904360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum immunoglobin and complement levels in Ghanaian sickle cell patients in the steady asymptomatic state.
    Akanmori BD; Adjei AA; Nyarko AK; Ankra-Badu G; Gyan B; Yamamoto S
    East Afr Med J; 1991 May; 68(5):378-82. PubMed ID: 1935733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.